Opinion|Videos|July 29, 2024
Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant
A panel of experts discuss navigating 2L treatment strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are your perceptions on efficacy and safety data on PROTAC
ASCO 2024 #TPS1131 TACTIVE-K: Phase 1b/2 study of vepdegestrant plus CDK4i PF-07220060
- What are your perceptions on efficacy and safety data on SERM:
- Lasoxifene:
ASCO 2024 #TPS1127 : Phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib
- Lasoxifene:
- How do these options compare? Why might you choose one of these options vs fulvestrant?
Advertisement
Related to this article
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/19
2
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
3
Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC
4
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options
5